PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 86 filers reported holding PARATEK PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $23,968 | -100.0% | 12,817 | -47.8% | 0.00% | – |
| Q3 2022 | $63,058,000 | +3.8% | 24,536 | -22.1% | 0.00% | – |
| Q2 2022 | $60,756,000 | -50.0% | 31,480 | -23.1% | 0.00% | – |
| Q1 2022 | $121,544,000 | -44.3% | 40,924 | -15.8% | 0.00% | – |
| Q4 2021 | $218,322,000 | +463.8% | 48,624 | +510.3% | 0.00% | – |
| Q3 2021 | $38,720,000 | +241.0% | 7,967 | +378.5% | 0.00% | – |
| Q2 2021 | $11,355,000 | -71.6% | 1,665 | -70.6% | 0.00% | – |
| Q1 2021 | $39,981,000 | -19.4% | 5,663 | -28.5% | 0.00% | – |
| Q4 2020 | $49,598,000 | -1.5% | 7,923 | -14.9% | 0.00% | – |
| Q3 2020 | $50,351,000 | +362.6% | 9,307 | +346.4% | 0.00% | – |
| Q2 2020 | $10,884,000 | -66.0% | 2,085 | -79.5% | 0.00% | – |
| Q1 2020 | $32,017,000 | +72.9% | 10,164 | +121.2% | 0.00% | – |
| Q4 2019 | $18,514,000 | -16.9% | 4,594 | -11.0% | 0.00% | – |
| Q3 2019 | $22,291,000 | +56.2% | 5,160 | +44.3% | 0.00% | – |
| Q2 2019 | $14,268,000 | -60.2% | 3,576 | -46.5% | 0.00% | – |
| Q1 2019 | $35,810,000 | +268.5% | 6,681 | +566.8% | 0.00% | – |
| Q3 2018 | $9,719,000 | -4.9% | 1,002 | 0.0% | 0.00% | – |
| Q2 2018 | $10,220,000 | -85.7% | 1,002 | -81.8% | 0.00% | – |
| Q1 2018 | $71,409,000 | -20.3% | 5,493 | +9.8% | 0.00% | – |
| Q4 2017 | $89,572,000 | +49.6% | 5,004 | +109.7% | 0.00% | – |
| Q3 2017 | $59,889,000 | -1.8% | 2,386 | -5.7% | 0.00% | – |
| Q2 2017 | $60,997,000 | +3961.1% | 2,531 | +3144.9% | 0.00% | – |
| Q1 2017 | $1,502,000 | -90.4% | 78 | -92.4% | 0.00% | – |
| Q4 2016 | $15,723,000 | -6.8% | 1,021 | -21.3% | 0.00% | – |
| Q3 2016 | $16,874,000 | +115.5% | 1,297 | +130.4% | 0.00% | – |
| Q2 2016 | $7,831,000 | -82.7% | 563 | -76.4% | 0.00% | – |
| Q4 2015 | $45,338,000 | -1.4% | 2,390 | -1.2% | 0.00% | – |
| Q3 2015 | $45,961,000 | +75.7% | 2,419 | +138.3% | 0.00% | – |
| Q2 2015 | $26,157,000 | – | 1,015 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |